Tag: ozempic

  • The Aesthetic Pharmaceutical Complex (a College Essay Prompt)

    The Aesthetic Pharmaceutical Complex (a College Essay Prompt)

    Write a 1,700-word argumentative essay that evaluates this claim: GLP-1 weight-loss drugs (e.g., Ozempic/Wegovy) offer a Faustian bargain–they blunt appetite and deliver rapid results, but at significant cultural, moral, and social costs. Examine whether these drugs simply cure an individual problem or whether they reshape appetite, pleasure, gender and marital dynamics, class inequality, body aesthetics, and personal agency in ways that should alarm us.

    Use Rebecca Johns (“A Diet Writer’s Regrets”), Johann Hari (“A Year on Ozempic…”), Harriet Brown (“The Weight of the Evidence”), Sandra Aamodt (“Why You Can’t Lose Weight on a Diet”), and at least two additional reputable sources of your choice. Address both sides: acknowledge the medical benefits (for diabetes, metabolic disease, disability reduction) while testing the claim that GLP-1s amount to a societal deal with the devil — trading desire, culinary culture, and autonomy for narrow aesthetic and market outcomes.

    Be sure to define terms (e.g., “Faustian bargain,” “GLP-1 drugs,” “body aesthetics”), offer evidence, and include a clear counterargument and rebuttal.


    Five Sample Thesis Statements (with mapping components)

    1. Thesis 1
      GLP-1 drugs are a Faustian bargain: they deliver rapid weight loss and metabolic benefit, but they also erode culinary pleasure, exacerbate social inequality, and replace disciplined habits with pharmaceutical dependence.
    • Mapping: (1) immediate medical and psychological benefits, (2) cultural costs to food and pleasure, (3) social/economic consequences and dependence.
    1. Thesis 2
      While GLP-1 medications can rescue lives in a clinical sense, their mainstreaming industrializes thinness—privileging aesthetics over health, amplifying economic divides, and outsourcing self-control to corporations and prescribers.
    • Mapping: (1) clinical life-saving benefits, (2) commercialization of body aesthetics, (3) economic and ethical fallout.
    1. Thesis 3
      GLP-1 drugs pose an ethical dilemma: they promise to erase cravings and curb addiction, but in doing so they risk flattening human desire, unsettling intimate relationships, and converting a public-health problem into a luxury aesthetic market.
    • Mapping: (1) pharmacological suppression of appetite, (2) impact on relationships and social life, (3) marketization and inequality.
    1. Thesis 4
      The rise of GLP-1s reframes weight management from moral failing to medicalized consumerism—undeniable benefits for some masked by troubling costs: cultural loss, shifting marital dynamics, and a dangerous dependence on biotech fixes.
    • Mapping: (1) medical reframing of obesity, (2) cultural and interpersonal costs, (3) risks of technological dependence.
    1. Thesis 5
      GLP-1 drugs give individuals the power to silence hunger, but that power comes tethered to troubling social outcomes: it amplifies privilege, intensifies pressure for aesthetic conformity, and weakens the role of habit and self-discipline in healthy living.
    • Mapping: (1) appetite suppression and individual gains, (2) exacerbation of aesthetic and class pressure, (3) erosion of habit-based agency.

    Counterargument (fair, strong):
    Proponents of GLP-1 drugs argue that calling them a “Faustian bargain” ignores the very real medical and social benefits these medications deliver. For many patients—especially those with type 2 diabetes, obesity-related hypertension, or mobility-limiting weight—GLP-1s reduce blood sugar, lower cardiovascular risk, and unlock functional gains that years of dieting could not. Early reports also show improvements in mood, self-efficacy, and social participation: when chronic hunger is quieted, people can exercise more, sleep better, and engage with life instead of being consumed by food preoccupation. From this perspective, the drugs restore agency rather than remove it; they are tools that expand options for people trapped by biology, food environments, and limited access to behavioral medicine. To label them morally corrosive risks stigmatizing patients who finally find relief.

    Rebuttal:
    That claim deserves respect—but it doesn’t dissolve the deeper social harms that mainstreaming GLP-1s threatens to produce. Medicine can relieve individual suffering while simultaneously reshaping culture in ways that reward aesthetic conformity and widen inequality: when a pharmaceutical becomes the fastest route to thinness, weight status shifts further from a health metric to a marketable badge of status, attainable first by those with money, time, and prescriber access. The drugs also substitute biochemical fixes for social solutions—affordable nutritious food, safer neighborhoods for exercise, workplace protections—that address root causes of metabolic disease; this medicalization risks absolving policymakers and corporations of responsibility. Finally, the long-term psychosocial costs are real: appetite suppression can blunt pleasure and disrupt food’s role as social glue, and couples who diverge in access to these drugs face novel tensions over desirability, divided resources, and identity. In short, GLP-1s can be miracles for patients; they can also be catalysts for cultural and economic shifts that deserve critical scrutiny before we call the bargain a fair trade.

  • The Skinny Kingdom Denied

    The Skinny Kingdom Denied

    When it comes to convincing your healthcare plan to cover GLP-1 drugs like Mounjaro or Ozempic, prepare to enter the bureaucratic Twilight Zone. You might think being thirty or forty pounds overweight with blood pressure, cholesterol, and triglycerides inching toward DEFCON 2 would qualify you for a pharmaceutical lifeline. But no—your semi-morbid condition isn’t morbid enough. You’re not quite in the “Skinny Kingdom” yet. You’re stuck in the purgatory of “almost sick,” where the medical advice is to do what 80% of people can’t manage long-term: lose weight the old-fashioned way. Cue the eye-roll and the salad.

    This is where I live—too metabolically misaligned for comfort, but too “not dying fast enough” for insurance. So without the aid of GLP-1 wonder-drugs, I’ve been forced to build my own survival kit. Enter: the diet blog. Yes, that hackneyed relic of the internet. One evolutionary rung above the YouTube weight-loss vlog, and about one click away from a Pinterest board full of quinoa regret. But here’s my defense: writing this thing keeps me sane. First, let’s acknowledge the stakes. I’m attempting to succeed at something with an 80% failure rate. If journaling helps me thread the needle between health and hoagies, I deserve at least a participation trophy. Second, maybe—just maybe—my hard-earned insights might help someone else. Third, I need a breadcrumb trail for myself. Because when the binge fog clears, I need a record of how I got out of the woods.

    But let’s get this straight: if I’m going to write a diet blog, it comes with rules.
    Rule #1: No hawking miracle powders or gut-cleansing teas. This isn’t a supplement commercial. It’s a field report from the front lines of temptation.
    Rule #2: No ab selfies. No one asked, and no one wants to see the cinematic arc of my belly fat.
    Rule #3: No sanctimonious “one-size-fits-all” advice. What works for me may not work for you. I’m here to offer humility, not doctrine.
    Rule #4: Keep it funny. We live in a world where 2,000-calorie muffins are marketed as breakfast. If you can’t laugh at that, you’re doomed.
    Rule #5: No performative pity. Yes, self-discipline is hard. But I’m not marching across Antarctica—I’m just saying no to a Costco cheesecake. Keep perspective.

    If there’s a unifying thesis to this blog, it’s this: self-indulgence is a false god. The man who eats without limits is not happier—he’s just momentarily sedated. True satisfaction comes from self-possession, not pastry. This isn’t about vanity or some fantasy of being a low-body-fat Spartan. It’s about dignity. The mature eater is the happier eater. And if I have to claw my way there without the help of Ozempic, so be it. I’ll blog my way through the absurdity. One disciplined bite at a time.

  • The Gospel According to Mounjaro and ChatGPT

    The Gospel According to Mounjaro and ChatGPT

    The other day I was listening to Howard Stern and his co-host Robin Quivers talking about how a bunch of celebrities magically slimmed down at the same time. The culprit, they noted, was Ozempic—a drug available mostly to the rich. While they laughed about the side effects, such as incontinence, “Ozempic face” and “Ozempic butt,” I couldn’t help but see these grotesque symptoms as a metaphor for the Ozempification of a society hooked on shortcuts. They enjoyed some short-term benefits but the side effects were far worse than the supposed solution. Ozempification was strikingly evident in AI-generated essays–boring, generic, surface-level, cliche-ridden, just about worthless. Regardless of how well structured and logically composed, these essays have the telltale signs of “Ozempfic face” and “Ozempic butt.” 

    As a college writing instructor, I’m not just trying to sell academic honesty. I’m trying to sell pride. As I face the brave new world of teaching writing in the AI era, I’ve realized that my job as a college instructor has morphed into that of a supercharged salesman. And what am I selling? No less than survival in an age where the very tools meant to empower us—like AI—threaten to bury us alive under layers of polished mediocrity. Imagine it: a spaceship has landed on Earth in the form of ChatGPT. It’s got warp-speed potential, sure, but it can either launch students into the stars of academic brilliance or plunge them into the soulless abyss of bland, AI-generated drivel. My mission? To make them realize that handling this tool without care is like inviting a black hole into their writing.

    As I fine-tune my sales pitch, I think about Ozempic–that magic slimming drug, beloved by celebrities who’ve turned from mid-sized to stick figures overnight. Like AI, Ozempic offers a seductive shortcut. But shortcuts have a price. You see the trade-off in “Ozempic face”—that gaunt, deflated look where once-thriving skin sags like a Shar-Pei’s wrinkles—or, worse still, “Ozempic butt,” where shapely glutes shrink to grim, skeletal wiring. The body wasn’t worked; it was bypassed. No muscle-building, no discipline. Just magic pill ingestion—and what do you get? A husk of your former self. Ozempified.

    The Ozempification of writing is a marvel of modern mediocrity—a literary gastric bypass where prose, instead of slimming down to something sleek and muscular, collapses into a bloated mess of clichés and stock phrases. It’s writing on autopilot, devoid of tension, rhythm, or even the faintest trace of a soul. Like the human body without effort, writing handed over to AI without scrutiny deteriorates into a skeletal, soulless product: technically coherent, yes, but lifeless as an elevator pitch for another cookie-cutter Marvel spinoff.

    What’s worse? Most people can’t spot it. They think their AI-crafted essay sparkles when, in reality, it has all the charm of Botox gone wrong—rigid, lifeless, and unnervingly “off.” Call it literary Ozempic face: a hollowed-out, sagging simulacrum of actual creativity. These essays prance about like bargain-bin Hollywood knock-offs—flashy at first glance but gutless on closer inspection.

    But here’s the twist: demonizing AI and Ozempic as shortcuts to ruin isn’t the full story. Both technologies have a darker complexity that defies simplistic moralizing. Sometimes, they’re necessary. Just as Ozempic can prevent a diabetic’s fast track to early organ failure, AI can become a valuable tool—if wielded with care and skill.

    Take Rebecca Johns’ haunting essay, “A Diet Writer’s Regrets.” It rattled me with its brutal honesty and became the cornerstone of my first Critical Thinking essay assignment. Johns doesn’t preach or wallow in platitudes. She exposes the failures of free will and good intentions in weight management with surgical precision. Her piece suggests that, as seductive as shortcuts may be, they can sometimes be life-saving, not soul-destroying. This tension—between convenience and survival, between control and surrender—deserves far more than a knee-jerk dismissal. It’s a line we walk daily in both our bodies and our writing. The key is knowing when you’re using a crutch versus when you’re just hobbling on borrowed time. 

    I want my students to grasp the uncanny parallels between Ozempic and AI writing platforms like ChatGPT. Both are cutting-edge solutions to modern problems: GLP-1 drugs for weight management and AI tools for productivity. And let’s be honest—both are becoming necessary adaptations to the absurd conditions of modern life. In a world flooded with calorie-dense junk, “willpower” and “food literacy” are about as effective as handing out umbrellas during a tsunami. For many, weight gain isn’t just an inconvenience—it’s a life-threatening hazard. Enter GLP-1s, the biochemical cavalry.

    Similarly, with AI tools quickly becoming the default infrastructure for white-collar work, resisting them might soon feel as futile as refusing to use Google Docs or Windows. If you’re in the information economy, you either adapt or get left behind. But here’s the twist I want my students to explore: both technologies, while necessary, come with strings attached. They save us from drowning, but they also bind us in ways that provoke deep, existential anguish.

    Rebecca Johns captures this anguish in her essay, “A Diet Writer’s Regrets.” Ironically, Johns started her career in diet journalism not just to inform others, but to arm herself with insider knowledge to win her own weight battles. Perhaps she could kill two birds with one stone: craft top-tier content while secretly curbing her emotional eating. But, as she admits, “None of it helped.” Instead, her career exploded along with her waistline. The magazine industry’s appetite for diet articles grew insatiable—and so did her own cravings. The stress ate away at her resolve, and before long, she was 30 pounds heavier, trapped by the very cycle she was paid to analyze.

    By the time her BMI hit 45 (deep in the obesity range), Johns was ashamed to tell anyone—even her husband. Desperate, she cycled through every diet plan she had ever recommended, only to regain the weight every time. Enter 2023. Her doctor handed her a lifeline: Mounjaro, a GLP-1 drug with a name as grand as the results it promised. (Seriously, who wouldn’t picture themselves triumphantly hiking Mount Kilimanjaro after hearing that name?) For Johns, it delivered. She shed 80 pounds without white-knuckling through hunger pangs. The miracle wasn’t just the weight loss—it was how Mounjaro rewired her mind.

    “Medical science has done what no diet-and-exercise plan ever could,” she writes. “It changed my entire relationship with what I eat and when and why.” Food no longer controlled her. But here’s the kicker: while the drug granted her a newfound sense of freedom, it also raises profound questions about dependence, control, and the shifting boundaries of human resilience—questions not unlike those we face with AI. Both Ozempic and AI can save us. But at what cost? 

    And is the cost of not using these technologies even greater? Rebecca Johns’ doctor didn’t mince words—she was teetering on the edge of diabetes. The trendy gospel of “self-love” and “body acceptance” she had once explored for her articles suddenly felt like a cruel joke. What’s the point of “self-acceptance” when carrying extra weight could put you six feet under?

    Once she started Mounjaro, everything changed. Her cravings for rich, calorie bombs disappeared, she got full on tiny portions, and all those golden nuggets of diet advice she’d dished out over the years—cut carbs, eat more protein and veggies, avoid snacks—were suddenly effortless. No more bargaining with herself for “just one cookie.” The biggest shift, however, was in her mind. She experienced a complete mental “reset.” Food no longer haunted her every waking thought. “I no longer had to white-knuckle my way through the day to lose weight,” she writes.

    Reading that, I couldn’t help but picture my students with their glowing ChatGPT tabs, no longer caffeinated zombies trying to churn out a midnight essay. With AI as their academic Mounjaro, they’ve ditched the anxiety-fueled, last-minute grind and achieved polished results with half the effort. AI cushions the process—time, energy, and creativity now outsourced to a digital assistant.

    Of course, the analogy isn’t perfect. AI tools like ChatGPT are dirt-cheap (or free), while GLP-1 drugs are expensive, scarce, and buried under a maze of insurance red tape. Johns herself is on borrowed time—her insurance will stop covering Mounjaro in just over a year. Her doctor warns that once off the drug, her weight will likely return, dragging her health risks back with it. Faced with this grim reality, she worries she’ll have no choice but to return to the endless cycle of dieting—“white-knuckling” her days with tricks and hacks that have repeatedly failed her.

    Her essay devastates me for many reasons. Johns is a smart, painfully honest narrator who lays bare the shame and anguish of relying on technology to rescue her from a problem that neither expertise nor willpower could fix. She reports on newfound freedom—freedom from food obsession, the physical benefits of shedding 80 pounds, and the relief of finally feeling like a more present, functional family member. But lurking beneath it all is the bitter truth: her well-being is tethered to technology, and that dependency is a permanent part of her identity.

    This contradiction haunts me. Technology, which I was raised to believe would stifle our potential, is now enhancing identity, granting people the ability to finally become their “better selves.” As a kid, I grew up on Captain Kangaroo, where Bob Keeshan preached the gospel of free will and positive thinking. Books like The Little Engine That Could drilled into me the sacred mantra: “I think I can.” Hard work, affirmations, and determination were supposed to be the alchemy that transformed character and gave us a true sense of self-worth.

    But Johns’ story—and millions like hers—rewrite that childhood gospel into something far darker: The Little Engine That Couldn’t. No amount of grit or optimism got her to the top of the hill. In the end, only medical science saved her from herself. And it terrifies me to think that maybe, just maybe, this is the new human condition: we can’t become our Higher Selves without technological crutches.

    This raises questions that I can’t easily shake. What does it mean to cheat if technology is now essential to survival and success? Just as GLP-1 drugs sculpt bodies society deems “acceptable,” AI is quietly reshaping creativity and productivity. At what point do we stop being individuals who achieve greatness through discipline and instead become avatars of the tech we rely on? Have we traded the dream of self-actualization for a digital illusion of competence and control?

    Of course, these philosophical quandaries feel like a luxury when most of us are drowning in the realities of modern life. Who has time to ponder free will or moral fortitude when you’re working overtime just to stay afloat? Maybe that’s the cruelest twist of all. Technology hasn’t just rewritten the rules—it’s made them inescapable. You adapt, or you get left behind. And maybe, somewhere deep down, we all already know which path we’re on.